Myotonic dystrophy type 1 (DM1) is caused by a CTG expansion mutation located in the 3' untranslatedportion of the dystrophica myotonica protein kinase gene. The identification and characterization of RNAbindingproteins that interact with expanded CUG repeats and the discovery that a similar transcribed butuntranslated CCTG expansion in an intron causes myotonic dystrophy type 2 (DM2), have uncovered a newtype of mechanism in which microsatellite expansion mutations cause disease through an RNA gain offunction mechanism in which CUG and CCUG expansion transcripts lead to the dysregulation of key RNAbindingproteins, including muscleblind (MbnH) and CUG-binding protein (CUG-BP), which in turn lead to thedownstream dysregulation of specific set of genes that cause the multisystemic features common to bothdiseases. Although the CNS deficits are one of the most clinically significant aspects of DM, the molecularmechanisms underlying these changes are unclear. Only DM1 causes developmental defects, includingmental retardation, but both forms of DM result in degenerative CNS effects that have not yet been wellcharacterized. The focus of this proposal is to characterize the CNS effects of the DM1 and DM2 mutationsin patients through imaging studies and neuropsychological testing and to relate these changes to theunderlying molecular deficits through the generation and characterization of mouse models. To accomplishthese goals the following Projects and Cores are proposed as part of our overall Program entitled: MyotonicDystrophy: Molecular Pathophysiology and CNS Effects.Project 1: Temporal/spatial RNA expression effects in DM1 and DM2Project 2: Mechanisms of RNA-Mediated CNS Pathogenesis in Myotonic DystrophyProject 3: Structural and Functional CNS Changes in Children with Myotonic Dystrophy Type 1Core A: Neuropathology and Optical Imaging CoreCore B: Administrative Core

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Program Projects (P01)
Project #
Application #
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Program Officer
Porter, John D
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Florida
Schools of Medicine
United States
Zip Code
Pattamatta, Amrutha; Cleary, John D; Ranum, Laura P W (2018) All in the Family: Repeats and ALS/FTD. Trends Neurosci 41:247-250
Sznajder, ?ukasz J; Thomas, James D; Carrell, Ellie M et al. (2018) Intron retention induced by microsatellite expansions as a disease biomarker. Proc Natl Acad Sci U S A 115:4234-4239
Chen, Gang; Carter, Russell E; Cleary, John D et al. (2018) Altered levels of the splicing factor muscleblind modifies cerebral cortical function in mouse models of myotonic dystrophy. Neurobiol Dis 112:35-48
Cleary, John Douglas; Pattamatta, Amrutha; Ranum, Laura P W (2018) Repeat-associated non-ATG (RAN) translation. J Biol Chem 293:16127-16141
Thomas, James D; Sznajder, ?ukasz J; Bardhi, Olgert et al. (2017) Disrupted prenatal RNA processing and myogenesis in congenital myotonic dystrophy. Genes Dev 31:1122-1133
Cleary, John Douglas; Ranum, Laura Pw (2017) New developments in RAN translation: insights from multiple diseases. Curr Opin Genet Dev 44:125-134
Grima, Jonathan C; Daigle, J Gavin; Arbez, Nicolas et al. (2017) Mutant Huntingtin Disrupts the Nuclear Pore Complex. Neuron 94:93-107.e6
Nakamori, Masayuki; Hamanaka, Kohei; Thomas, James D et al. (2017) Aberrant Myokine Signaling in Congenital Myotonic Dystrophy. Cell Rep 21:1240-1252
Zu, Tao; Cleary, John D; Liu, Yuanjing et al. (2017) RAN Translation Regulated by Muscleblind Proteins in Myotonic Dystrophy Type 2. Neuron 95:1292-1305.e5
Moloney, Christina; Rayaprolu, Sruti; Howard, John et al. (2016) Transgenic mice overexpressing the ALS-linked protein Matrin 3 develop a profound muscle phenotype. Acta Neuropathol Commun 4:122

Showing the most recent 10 out of 57 publications